LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases

From last year—for RA, MS, etc.

• LPX-TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin (Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and multiple sclerosis with the intent to expand into additional therapeutic indications.
• In healthy adults, LPX-TI641 was orally bioavailable and was safe and well tolerated up to the highest tested doses.
• Exploratory pharmacodynamic endpoints showed an exposure-dependent, statistically significant increase in both regulatory T and B cells (T-regs and B-regs) compared to pooled placebo group.
• LAPIX cleared a second Investigational New Drug (IND) for LPX-TI641 with the rheumatology division at the US-FDA.
• LAPIX will initiate a Phase 1b study for Rheumatoid arthritis (RA) in Q4 2024.

https://www.biospace.com/press-rele...i641-for-the-treatment-of-autoimmune-diseases